

tuted β -cyclodextrin, to act as a solubilizer for the itraconazole or saperconazole;

(c) an aqueous acidic medium as bulk liquid carrier;

(d) an alcoholic co-solvent selected from the group consisting of ethanol, propylene glycol and glycerol;

(e) one or more pharmaceutically acceptable intense sweeteners plus one or more bulk sweeteners; and

(f) one or more pharmaceutically acceptable flavors.

Amend Claim 3 to read as follows:

²
~~3~~.(Amended) A formulation according to claim [1 or 2] ¹~~11~~ wherein [the antifungal is itraconazole or saperconazole and] the cyclodextrin is hydroxypropyl- β -cyclodextrin having an M.S. in the range of 0.35 to 0.50 and containing less than 1.5% unsubstituted β -cyclodextrin.

Claims 8 and 9, line 1 of each claim, after the word "claim" delete "2" and insert therefor --- 11 ---.

REMARKS

Reconsideration of this application in its amended form is respectfully requested.